, and are not likely to cause health problems during a man's lifetime. Overtreatment is a well-recognized consequence of the overdetection of prostate cancer, and is particularly problematic in individuals who are at a low risk of aggressive or lethal disease, who might be exposed to the morbidities of treatment with little or no benefit in terms of cancer-specific survival 6 . Active surveillance (AS) focuses on the prevention of overtreatment by selecting patients with established features of low-risk prostate cancer and strictly monitoring these features over time in order to recognize a need for risk reclassification that would justify radical treatment, although still with a curative intent 7 . The current challenge is to identify the specific subset(s) of patients that harbour more-aggressive disease, at a sufficiently early stage that curative therapy remains a possibility, thereby allowing the majority of patients with prostate cancer to retain their current quality of life, without experiencing the adverse effects of unnecessary treatments 8 . Various institution-specific eligibility protocols have been proposed for the identification of patients for whom AS would be appropriate 2 . Currently, published reports that contain formal protocols for AS are available for 
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Abstract | In the past decade active surveillance (AS) of men with localized prostate cancer has become an increasingly popular management option, and a range of clinical guidelines have been published on this topic. Existing guidelines regarding AS for prostate cancer vary widely, but predominantly state that the most suitable patients for AS are those with pretreatment clinical stage T1c or T2 tumours, serum PSA levels <10 ng/ml, biopsy Gleason scores of 6 or less, a maximum of one or two tumour-positive biopsy core samples and/or a maximum of 50% of cancer per core sample. Following initiation of an AS programme, most guidelines recommend serial serum PSA measurements, digital rectal examinations and surveillance biopsies to check for and identify pathological indications of tumour progression. Definitions of disease reclassification and progression differ among guidelines and multiple criteria for initiation of definitive treatment are proposed. The variety of descriptions of criteria for clinically insignificant prostate cancer indicates a lack of consensus on optimal AS and intervention thresholds. A single set of guidelines are needed in order to reduce variations in clinical practice and to optimize clinical decision-making. To enable truly evidence-based guidelines, further research that combines existing evidence, while also gathering information from more long-term studies is needed.
16 unique cohorts of men with prostate cancer, worldwide 9 . Use of many different AS protocols has been reported in the literature, although these vary in both their inclusion criteria and monitoring procedures 9 . To date, the effectiveness of AS protocols has not been validated in randomized controlled trials. More importantly, these protocols have not been examined with respect to their effects upon overall and/or prostate cancer-specific mortality outcomes 9 . A reliable method for identifying tumours that are clinically insignificant is still lacking and triggers for the implementation of curative measures, such as radical prostatectomy and radiation treatments, have yet to be established.
A number of guidelines have been published to assist both clinicians and patients in critically important treatment-related decision-making, these include criteria for enrolment of patients in AS programmes and their subsequent management [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . However, the comparability of the recommendations contained in these various guidelines is unknown. In this Review, existing guidelines on the use of AS in men with clinically insignificant prostate cancer are described and compared, including a comprehensive overview of the recommendations regarding patient selection, frequency and type of monitoring and the criteria for initiation of definitive treatment.
Characteristics of the guidelines
Half of all published guidelines on AS of men with prostate cancer identified in our literature search were developed in Europe (eight) 12, [14] [15] [16] [17] [18] [19] 23 ; three in Canada 10, 20, 24 ; two in the USA 11, 13 ; one in Asia 21 , one in New Zealand 22 and one in Australia 25 (TABLE 1) . The guidelines were published between 2006 and 2015, and most of these have undergone subsequent updates. Most guidelines are published in English, except for the The Finnish Medical Society Duodecim (FCCG) 23 , the Dutch Urological Association (DUA) 16 and German Society of Urology (GSU) 15 guidelines, which are published in Finnish, Dutch and German, respectively. Almost all guidelines are on the diagnosis, treatment and/or the management of patients with prostate cancer in general and include information on AS only as an alternative management strategy [10] [11] [12] [13] [14] [15] [16] [17] [19] [20] [21] [22] [23] 25 . Two organizations, the South East Scotland Cancer Network (SCAN) 18 and Cancer Care Ontario (CCO) Evidence Based Guideline Quality Initiative 24 have published guidelines that are specifically focused on AS.
Quality assessment The Appraisal of Guidelines for Research and Evaluation (AGREE II) Instrument
26 is a validated generic tool designed for evaluation of the process of guideline development and provides a systematic framework for assessing key components of clinical guideline quality 27 . The instrument consists of 23 items grouped into six domains: scope and purpose; stakeholder involvement; rigour of development; clarity and presentation; applicability; and editorial independence 27 . One item is added to score the overall quality of the guideline. Each item is rated from one (strongly disagree or no information provided on this item) to seven (strongly agree) 27 . As outlined in the AGREE II manual, domain scores for AS protocols were calculated by summing all scores of the individual items in a domain, and by scaling the total as a percentage of the maximum possible score for that domain: ((obtained score -minimum possible score)/(maximum possible score -minimum possible score))×100. Scores >60% were defined as 'good' , scores of 30-60% as ' moderate' and scores lower than 30% as 'poor' quality 27 . According to this assessment, 12 of the guidelines are of 'good' quality: those provided by the American urological association (AUA) 13 ; the European Association of Urology (EAU) 14 ; the National Comprehensive Cancer Network (NCCN) 11 20 ; and the Singapore Ministry of Health (NCCS) 21 . Inadequate and/or incomplete reporting cannot be ruled out as a reason for lower quality scores.
Risk groups and surveillance
Pretreatment risk estimation tools serve to stratify patients on the basis of perceived clinical risk and are employed in identifying candidates for AS. According to most of the guidelines described in this Review, patients with prostate cancer should be stratified into three risk groups: low, intermediate and high risk (TABLE 2) , mostly based on tumour stage and grade, and serum PSA levels. The NCCN 11 and the PCT 22 additionally include 'very low risk' as a suitable risk profile of patients who are eligible for AS. According to recommendations contained in all guidelines included in this Review, AS is primarily recommended for patients with low-risk tumours. Various definitions of low-risk prostate cancer exist in these guidelines, as specified by different combinations of clinical criteria including clinical and pathological characteristics (such as tumour stage, serum PSA levels, biopsy Gleason score, tumour volume and serum PSA density). In certain guidelines, patients must possess numerous concurrent low-risk features in order to be classified as 'low-risk' , although in others, certain individual clinical criteria might lead to a patient being classified as having an intermediate, or high risk of tumour
Key points
• A number of guidelines have been published that include criteria for active surveillance (AS) enrolment and subsequent management to assist clinicians and patients in critically important treatment related decision-making • Consensus on inclusion criteria, surveillance schedules and intervention thresholds is currently lacking • The future of AS and its uptake as a management modality will depend on better patient selection and validated monitoring schedules to improve identification of disease progression • Combining existing evidence and gathering more long-term evidence is needed to derive a broadly supported guideline to reduce variations in clinical practice and to optimize clinical decision-making progression. Five guidelines, those provided by the AUA 13 , NICE 12 , DUA 16 , FCCG 23 and CCNS 10 , contain recommendations to select intermediate-risk patients with prostate cancer for AS. Two of these guidelines -from the AUA 13 and the DUA 16 -state that AS also remains a treatment option for patients with 'high-risk' prostate cancer. Both of these guidelines specifically refer to AS and not to watchful waiting. In the AUA guidelines 13 , the term 'active surveillance' is used to refer to a monitoring program without initial treatment for patients with localized prostate cancer. This monitoring programme and its goals might be different based on specific patient and tumour characteristics and is distinct from watchful waiting, in which a lesser degree of monitoring is typically used, and treatment is generally instituted if metastases or symptoms develop 13 . The DUA guidelines 16 also acknowledge a meaningful difference between AS and watchful waiting. In AS, curative treatment is recommended if disease progression is detected, however, in watchful waiting the decision to start treatment relies on the progression of symptoms. The watchful waiting approach is typically used for the management of older patients who have substantial comorbidities. The DUA guidelines 16 contain the recommendation that AS can be considered for patients with intermediate-risk or high-risk prostate cancer if the age of the patient and/or his comorbidities negatively influence life expectancy. According to the AUA guidelines 13 , patients with high-grade tumours generally have a poor prognosis and are not suitable for AS, however, AS remains an option for the management of patients with high-risk localized prostate cancer, owing to the lack of evidence of superiority of any one therapy (including AS, interstitial prostate brachytherapy, external beam radiotherapy and radical prostatectomy) over another. ) also consider patients with serum PSA levels of 10-20 ng/ml to be eligible for AS and the CCNS guidelines 21 include the same recommendation at 10-19 ng/ml serum PSA. The AUA 13 and DUA 16 guidelines allow selection of patients with serum PSA levels >20 ng/ml for AS. Finally, five of the guidelines (those provided by the NCCN 11 18 , NCCS 21 and PCT 22 ) include the patient's life expectancy as an inclusion criterion. All of these guidelines apply a cut-off time of 10 years, either as a minimum or a maximum. Most guidelines (including those provided by the EAU 14 , NCCN 11 , KCE 17 and SCAN
18
) describe a life expectancy of >10 years as the ideal indication criterion for AS of patients with low-risk, or very-low-risk prostate cancer. The EAU 14 guidelines state that the patient's life expectancy can exceed 10 years once patients are informed of the lack of data on survival beyond 10 years. One set of guidelines (provided by the NCCS 21 ) recommends use of AS in men with a shorter life expectancy, specifically <10 years. The other three guidelines (those provided by the DUA 16 , FCCG 23 and PCT 22 ) state that the patient's life expectancy should be taken into account, but do not provide further details. ) state that the decision to start AS should be made in the light of the patient's individual preferences.
Summary of eligibility criteria
Multiple criteria have been proposed for identifying patients with prostate cancer who have a favourable prognosis and are, therefore, candidates for AS (TABLE 3) . Most available international guidelines recommend clinical risk stratification based on patients' tumour stage, serum PSA level, Gleason score, and estimated tumour volume as the primary means of refining patient selection. PSAD, the minimum number of prostate biopsy cores acquired, the patient's life expectancy, the presence of comorbidities and the patient's preferences have been advanced by some but have not, thus far, been universally adopted as risk stratification tools. Many variations in risk stratification schemes currently exist, guidelines predominantly recommend that the most suitable patients for AS are those with pretreatment clinical stage T1(c) or T2a prostate cancer, serum PSA <10 ng/ml, a biopsy Gleason score of six or less, a maximum of one or two tumour-positive biopsy core samples and/or a maximum of 50% of cancer per core.
Surveillance type and frequency
Of the 16 guidelines included, three guidelines (those provided by the AUA 13 , DUA 16 and PCFA
25
) do not provide explicit recommendations for the monitoring of patients as part of an AS programme.
Serum PSA measurements
Thirteen of the guidelines described in this Review recommend measurements of serum PSA during AS procedures. Four guidelines (those provided by the NCCN 11 , KCE 17 , CCNS 10 and PCT 22 ) state that serum PSA monitoring should be implemented at intervals no more often than every 6 months after the start of AS. The PCT 22 guidelines additionally state that serum PSA levels should be measured every 3 months if concerns about progression of the cancer exist. Three guidelines (those provided by the AHS 20 , CCO 24 and NCCS
21
) recommend serum PSA testing every 3-6 months after the start of AS, whereas four of the other guidelines (those provided by NICE 12 , the GSU 15 , SCAN 18 and I+CS 19 ) use different frequencies depending on the time that has passed since the start of AS. Two of these guidelines (those provided by the GSU 15 and SCAN 18 ) state that serum PSA should be measured every 3 months in the initial testing period of 1 year, and if the PSA level is stable within this period, then every 6 months subsequently. The I+CS 19 guidelines recommend a serum PSA test every 3 months in the initial testing period of 2 years, and if the serum PSA level is stable within this period, then every 6 months subsequently. The NICE 12 guidelines state that serum PSA levels should be checked every 3-4 months in the first year after commencing AS, and then every 3-6 months between 2-4 years and every 6 months in year 5 and thereafter. Finally, two guidelines (those provided by the EAU 14 and FCCG
23
) recommend serum PSA testing during AS, but do not suggest any specific interval lengths between measurement.
Digital rectal examination
Thirteen of the guidelines described in this Review recommend the use of a digital rectal examination (DRE) in order to monitor the tumour carefully during a programme of AS. Four guidelines (those provided by the NCCN 11 , AHS 20 , CCO 24 ) recommend the use of different intervals between successive DREs depending on the time that has passed since the start of AS. The NICE guidelines 12 recommend that a DRE should be conducted every 6-12 months if patients have low-risk prostate cancer, and are undergoing AS within the first 4 years of diagnosis, with an annual DRE subsequent to this 4-year period. Two guidelines (provided by the GSU 15 and I+CS 19 ) recommend a DRE every 3 months in the first 2 years after diagnosis, subsequently reducing to DRE at 6-monthly intervals thereafter (provided that 
Repeat biopsy sampling
Repeat prostate biopsy sampling is used during AS in order to limit sampling error of the initial biopsy, that is, to confirm the initial biopsy findings and, periodically, to evaluate pathological progression of the tumour grade and/or volume, which might influence prognosis and, hence, the decision to continue AS or to proceed to definitive local therapy.
Substantial variation exists in the recommended frequency at which rebiopsy procedures should be conducted. A total of 13 of the guidelines described in this Review provide guidance in this area. The NCCN guidelines 11 recommend intervals between biopsy sampling of at least 12 months, unless clinically indicated by a rising serum PSA level or findings of a DRE, or at 6 months if the initial biopsy procedure involved sampling of <10 cores or assessment findings are discordant (such as an observation of palpable tumour contralateral to the side of a tumour-positive biopsy sample). Three guidelines (those provided by NICE 12 , the KCE 17 and the PCT 22 ) recommend rebiopsy sampling at or within one year of diagnosis. According to the NICE 12 and PCT guidelines 22 , the frequency of rebiopsy sampling should be dictated by changes in serum PSA levels or clinical concerns of tumour progression based on prostate changes detected by DRE. The KCE guidelines 17 recommend the use of repeat biopsy sampling procedures, but also suggest that the optimal timing of such procedures cannot currently be defined. Seven guidelines (those provided by the GSU 15 , SCAN 18 , CCNS 10 , I+CS 19 , AHS 20 , CCO 24 and NCCS 21 ) recommend different frequencies of rebiopsy sampling depending upon the time that has passed since the start of AS. The AHS guidelines 20 recommend repeat biopsy sampling at an interval of 1-2 years after the original diagnosis, and then every 2-3 years thereafter, or as clinically indicated. The SCAN guidelines 18 recommend considering rebiopsy sampling within 6 months of diagnosis, and then after 1, 4, 7 and 10 years of AS. The I+CS guidelines 19 recommend rebiopsy sampling using a 1, 4 and 7 year timeframe, with at least 10 cores taken per biopsy procedure. The CCO guidelines 24 recommend rebiopsy sampling with a 12-14-core confirmatory transrectal ultrasonography (TRUS) biopsy procedure (including anterior-directed cores) within 6-12 months of diagnosis, and serial biopsy a minimum of every 3-5 years thereafter. The NCCS guidelines 21 suggest the use of rebiopsy sampling within 12-18 months and then less frequently thereafter. The EAU guidelines 14 state that surveillance strategies, including the optimum interval between clinical tests, should, among other factors, be based upon the findings of repeat biopsy sampling, although the optimal timing of the various clinical measurements taken during AS is still unclear. Finally, the FCCG guidelines 23 recommend use of repeat biopsy sampling during AS, but do not suggest any specific lengths of intervals between procedures. , MRI can be performed in patients whose serum PSA levels have increased, despite the biopsy sample being found to be tumour-negative on analysis; although this is not a strong recommendation, and more evidence is awaited. The NICE guidelines 12 recommend that multiparametric MRI (mpMRI) should be performed at enrolment, (if not previously performed) or if the clinician is concerned about changes in clinical parameters or serum PSA levels at any time during AS. The KCE guidelines 17 state that use of imaging can be considered each year. The CCO guidelines 24 suggest that use of mpMRI is indicated when a patient's clinical findings are discordant with the pathological findings, and that MRI is useful in identifying occult cancers or changes indicative of tumour progression in patients who are at risk.
Summary of surveillance type and frequency
Following initiation of AS, most guidelines recommend serial measurment of serum PSA levels, digital rectal examination and surveillance biopsy sampling in order to identify pathological progression. However, many uncertainties remain surrounding the optimal timing of these surveillance strategies. PSA kinetics and MRI are less frequently recommended as methods to identify whether or not a patients' cancer has progressed (TABLE 4).
Switching to definitive therapy A proportion of men with ostensibly low-grade, low-stage prostate cancer who are undergoing AS will experience changes that will indicate a need for disease reclassification during extended surveillance 29, 30 . As men's symptoms progress, or are reclassified beyond the initial inclusion criteria for AS (they no longer meet the entry criteria), treatment with curative intent is often recommended. Definitions of tumour progression or reclassification vary among the published guidelines and a number of criteria have been proposed for determining when to proceed with curative interventions (TABLE 4) . Five of the guidelines described in this study (those provided by the AUA 25 , EAU 14 , DUA 16 , PCT 27 and the PCFA 10 ) do not include criteria for switching from AS to definitive therapy. 23 and NCCS guidelines 21 recommend that all patients undergoing AS who are found to have a biopsy Gleason score of >6 (such as ≥3 + 4) on analysis of a repeat biopsy sample should be considered for switching to active therapy. The CCO guidelines 24 state that for patients with a Gleason score of ≥7 and/or who also have substantial increases in the volume of Gleason 6 tumour detected on analysis of a rebiopsy sample, consideration should be given to switching to active therapy. The I+CS guidelines 19 more generally recommend treatment in men with a PSA velocity >1ng/ml per year, or those with higher degree of tumour volume observed during a DRE.
Increase in tumour volume
Three guidelines, those provided by the GSU 15 , FCCG 23 and NCCS 21 , state that treatment should be recommended in men who have more than two tumour-positive biopsy sample cores; and four guidelines (those provided by the GSU 15 , SCAN 18 , AHS 20 and NCCS
21
) recommend that the extent of the cancer should not exceed 50% per core, if AS is to be continued. The SCAN guidelines 18 additionally recommend that ≤50% of the total number of cores should be affected by a patient's cancer for continued use of AS. Two guidelines (those provided by the NCCN 11 , and I+CS 19 ) contain more general descriptions. The NCCN guidelines 11 state that an increase in the number of tumour-positive biopsy sample cores or an increase in the extent of disease in tumour-positive sample cores upon rebiopsy is a trigger for switching to treatment. The I+CS guidelines 19 suggest a greater extension of the tumour in repeated biopsies. Four of the guidelines described in this Review (those provided by the AUA 13 , GSU 15 , I+CS 19 and AHS 20 ) include information on the minimum number of biopsy cores that should be sampled and all agree on a minimum number of 10 cores.
Other recommendations
Two guidelines (those provide by NICE 12 and the NCCS 21 ), in general, recommend initiation of active treatment if disease progression is observed. Furthermore, the FCCG guidelines 23 simply state that active treatment is recommended if a man's prostate cancer is reclassified as being clinically relevant. According to three guidelines (those provided by NICE 12 , the AHS 20 and NCCS 21 ), the decision to proceed to radical treatment should be made on the basis of personal preferences 12, 20, 21 . According to the NICE guidelines 12 , the individual man's specific comorbidities and life expectancy should be taken into account when making a decision on proceeding to treatment.
Summary of switching criteria
Several of the guidelines described in this Review do not include any criteria on switching from AS to definitive therapy. Definitions of disease reclassification and progression differ between different guidelines, and multiple cri teria for initiation of treatment are proposed (TABLE 5) . Some guidelines advocate the initiation of curative treatment if progression to a higher-grade tumour (mainly described as Gleason pattern 4 or 5) is observed, or if an increase in the number of tumour-positive biopsy cores (>2 of a recommended minimum of 10 cores) or an increase in the extent of cancer per core sample (to >50% of cancer per tumour-positive core) is detected on analysis of surveillance biopsy samples. Clinical progression detected during DRE (although currently not clearly defined), a serum PSADT of <3 years, or a change in patient preference are also regularly described as risk reclassification criteria, leading to initiation of definitive treatment.
Considering protocols overall
In light of the high global prevalence of localized prostate cancer, AS has been widely implemented and numerous agencies have endorsed practice guidelines in this area. In total, 16 international guidelines advocate the use of AS as an initial option for disease management in men with localized prostate cancer, but many variations in recommended risk stratification schemes are found. Guidelines predominantly state that the most suitable patients for AS are those with pretreatment clinical stage T1(c) or T2 prostate cancer, serum PSA levels <10 ng/ml, biopsy Gleason scores of 6 or less, a maximum of one or two tumour-positive biopsy core samples and/or a maximum of 50% of cancer per biopsy core sample. Following initiation of AS, most guidelines advise the use of serial serum PSA measurements, DRE and surveillance biopsies to identify pathological tumour progression. The recommended intervals between these tests vary widely between guidelines. Definitions of disease reclassification and progression differ among guidelines and multiple criteria are proposed (TABLE 6 ). AS is increasingly being accepted as a treatment option for patients with localized prostate cancer, although, robust data from men with clinically insignificant prostate cancer who are undergoing AS guided by various protocols -especially from studies with long follow-up durations -is still limited. At present, two prospective studies of AS have published data available on long-term outcomes of men with favourable-risk prostate cancer 31, 32 . New data from the Johns Hopkins University School of Medicine on outcomes after AS show that higher PSA density (HR, 1.38 per 0.1 unit increase; 95% CI 1.22-1.56) at diagnosis, and a greater number of tumour-positive biopsy cores (HR, 1.35 for one additional positive core; 95% CI 1.19-1.53) were both found to be associated with a need for curative intervention, following multivariate analyses 31 . In a Canadian AS cohort, with a follow-up duration of 16 years, PSADT of less than 3 years was found to be a marker of more-aggressive disease (median time to progression, 5.12 versus 9.23 years in patients with longer PSADT; P = 0.002) 32 . Apart from these study reports 31, 32 , which were published after the majority of the guidelines described in this Review, only data from prospective clinical trials investigating AS that have a mean follow-up duration of <10 years are available 33 . This lack of robust evidence is reflected in the diversity of recommendations among the available guidelines on AS of men with clinically insignificant prostate cancer. Findings of a study conducted by Azmi et al. 34 in 2013 showed that a high level of agreement exists between the conclusions of various studies of AS, that patients with serum PSA levels ≤10 ng/ml and a biopsy sample Gleason score of ≤3 + 3 = 6 are appropriate for AS, although, clearly less agreement exists in terms of the most appropriate clinical tumour stage, number of tumour-positive biopsy core samples and patient age 34 . Furthermore, little consensus exists in the literature regarding how to optimally assess progression of localized prostate cancer; although, the majority of studies used serial measurements of serum PSA levels and DRE, with some also adding prostate biopsy sampling 34 . No consensus has been reached regarding the frequency of repeat investigations or on the most appropriate triggers for initiation of radical treatment across the various AS programmes 34 . To enable truly evidence-based guidelines to be issued, further research that combines existing evidence while also gathering information from more long-term studies is needed.
Patients with prostate cancer who have a tumour Gleason grade of ≤6 are extremely unlikely to progress to metastatic disease or die from their cancer 35 . However, some guidelines have taken the position that AS could be an appropriate management strategy for men with a Gleason score of ≥7 at diagnosis 10, 12, 13, 16, 23, 24 . Findings from a study with a large cohort demonstrate that the finding of a Gleason score of 8-10 on confirmatory biopsy is associated with early progression to metastasis 32 . The AUA guidelines 13 acknowledge this high risk of progression; however, these guidelines still recommend AS as a treatment option for patients with highrisk disease owing to the lack of evidence of superiority of any one therapy over another. Whether this approach is the correct one to follow is a matter of some debate.
Explanations for the observed variations between available guidelines on AS are speculative, but geographical variations should be taken into account. Different countries practice medicine in various ways and vary particularly in their approaches to the treatment of cancer 36 . These differences are likely a result of the existence of distinct national cultures, history and medical training 36 . For instance, major differences exist between the detection and treatment of prostate cancer in the USA and UK. Widespread use of serum-PSA based screening in the USA has resulted in a higher proportion of men being diagnosed with disease that is amenable to AS 37, 38 . In the UK -a country with relatively limited use of serum-PSA based screening -only a small minority of newly diagnosed patients with prostate cancer meet the criteria for low-risk disease 39 . An aggressive local philosophy with respect to prostate cancer screening might also correspond with an increased tendency towards treatment 40 . In the USA, the academic medical community and professional societies have become more accepting of AS of men with low-risk prostate cancer, although delaying the initiation of aggressive treatment is still not generally acceptable to most patients or their doctors 38 . By contrast, findings of a UK study published in 2010 showed that British men and doctors were more willing to accept AS with up to 39% opting for AS in 2006, compared with 0% in 2000 (REF. 39 ). The various available guidelines highlight the best practices for the diagnosis, treatment and/or the management of prostate cancer in different geographical areas. Whether or not these cross-cultural differences will ever be perfectly integrated into one global policy remains questionable.
The validation and clinical implementation of novel biomarkers might improve the identification of the most appropriate candidates for AS and will likely be reflected in future guidelines. Van den Bergh et al. 41 concluded that imaging and serum-based markers (such as PSA isoforms) might, in the future, improve the selection of patients for AS and their follow-up monitoring during AS 41 . In a review published in 2014, authors noted that a growing body of literature is available on patient characteristics, biopsy features and biomarkers with potential utility in AS 42 . For instance, patient age, race, and possibly family history are all factors that could be considered for patient selection. Also, consistent evidence suggests that a lower percentage of free PSA, higher Prostate Health Index, higher PSAD and greater biopsy core involvement at baseline all indicate a greater risk of progression 42 . Furthermore, evidence suggests that use of the biopsy-based 17-gene Genomic Prostate Score improves prediction of the presence or absence of adverse pathology and might help men with prostate cancer to make better-informed choices between AS and immediate treatment 43 . Following various advances in genomic and proteomic technologies, several new Clinical Laboratory Improvement Amendment-based laboratory-developed tests have become available that might also be useful in the differentiation of aggressive from nonaggressive forms of prostate cancer, such as Prolaris® (Myriad Genetics, Salt Lake City, Utah, USA) 44 . The 4Kscore® (Opko Health, Florida, USA) has also been shown to have proven diagnostic performance when used for detection of clinically significant prostate cancer and might be a useful tool in distinguishing men who have clinically significant disease and are most likely to benefit from a prostate biopsy from men with no cancer or indolent cancer 45 . In a systematic review on the use of MRI in men with low-risk or intermediaterisk prostate cancer who were considered suitable for AS, the researchers demonstrated that MRI is useful for the detection of clinically significant disease at initial clinical assessment of men considering AS 46 . In addition, MRI might be useful to confirm the absence of any large anteri or lesions that have been missed during routine diagnosis 47 . However, at present, no robust, formally published data are available that support the use of MRI in place of repeat standard biopsy sampling to detect progression of cancer over time 46 . Among biopsy sampling approaches, transrectal prostate biopsy sampling is internationally more common than transperineal prostate biopsy sampling (TPB). Findings of a study published in 2013, however, suggest that, in patients on AS programmes, a staging TPB might be an alternative approach for patients undergoing repeat biopsy in order to minimize the risk of serious infection 48 . Whether any role exists for these markers and monitoring tools in risk assessment during AS requires further study. Finally, quality of life, arguably, should have a role in the decision to initially pursue AS rather than active treatment and in the decision to switch from AS to active treatment 49 . However, no data from studies with long-term follow-up durations and suitable control groups are currently available, and more research is needed in this area. AS is currently an evolving treatment approach, with numerous challenges. Thus, it is advised that guideline writers should carefully follow the progress that is made within the field of AS, as the field is moving rapidly.
Challenges in reviewing AS guidelines
The use of electronic sources to identify guidelines for discussion in this Review might have introduced bias towards English language guidelines and guidelines produced by larger, well-established organizations 50 . The use of high-quality guidelines would improve health-related decision making, potentially resulting in enhanced health care quality and outcomes. Our own assessment using the AGREE II tool suggests that not all of the included guidelines are of 'good' quality. Some debate exists as to whether or not guidelines of 'moderate' quality should be used to guide patient care. Users of clinical practice guidelines need to know how much confidence they can place in the recommendations. Furthermore, the guidelines described in this Review have been developed by a number of leading organizations using different methodologies. For instance, discrepancies exist in the criteria used to grade the quality of evidence and to categorize the strength of the recommendations. These differences could be the source of conflicting recommendations 51 . Standardizing the processes used by leading urological organizations to develop clinical guidelines for the management of patients with prostate cancer would be beneficial to both clinicians and patients 51 
. Finally, substantial variation was observed in the year of publication of individual sets of guidelines, with several of the guidelines described in this Review published more than 5 years ago, without any subsequent updates, which could mean these are no longer in line with current clinical practice, thus leaving it up to clinicians to make up their own minds about how they manage patients on AS.
Future steps
Clearly, an unmet need exists for a worldwide consensus regarding criteria and protocols for AS. When developing a global guideline, the selection of topics, the composition of the guideline group, the work plan, the search for evidence and the involvement of clinical experts are all important 52 . An evidence-based consensus approach to developing guideline recommendations is considered the 'gold standard' . The development phase should, therefore, start by searching for scientific evidence and an assessment of its relevance and quality. As a next step, clinical experts should be involved to formulate and prioritize recommendations 52 . Owing to the possibility of one, or a few experts dominating discussions according to their own individual origin, background and experiences, structuring the discussions is recommended, for instance by using the Delphi Procedure 53 to quantitate 'expert opinion' . The entire process of developing guidelines should be transparent to the guideline user. The principal ben efit of a global guideline is to improve the consistency of (high quality) care. However, constructing a global guideline presents a unique challenge. Approaches to AS of men with prostate cancer differ across the world, the guideline should, therefore be both comprehensive and flexible enough to allow adaptation to the diverse settings and circumstances of day-to-day clinical practice. The development and publication of a set of global clinical practice guidelines are only the first steps in the process of improving patient care. To facilitate the applicability of such guidelines in daily care, cooperation with professional societies and associations is crucial. The clinical guideline should ideally be submitted for approval to an independent scientific council and to the professional urological organizations responsible 52 . Furthermore, collaboration should be sought with patient advocacy organizations, who could have an important role in promoting the guidelines among patients and their families.
One potential solution is the Movember Global Action Plan Active Surveillance project (GAP3)
, which was launched in August 2014. This initiative is an integrated project lasting 30 months and is being 
. This initiative will make significant contributions to this field of research by offering standard, evidence-based guidelines on AS. Clinicians will be able to use these guidelines to more confidently identify men that are suitable for active surveillance and to also decide whose prostate cancer has progressed and will, therefore, require treatment. Such guidelines will provide reassurance to men that they have made the best treatment choice for their type of disease.
Conclusions
Despite the ample availability of guidelines on AS for patients with prostate cancer, consensus on inclusion criteria, surveillance schedules and intervention thresholds is currently lacking. The future of AS and its uptake as a management modality will depend on better patient selection and validated monitoring schedules to improve the identification of disease progression. Combining existing evidence and gathering more long-term evidence is needed in order to derive a broadly supported guideline to reduce variation in clinical practice and to optimize clinical decision-making.
